ANVS Annovis Bio: תחזית צמיחת רווח נקי למניה לשנה הבאה

The profitability of Annovis Bio, Inc. (ANVS) depends on the success of buntianesan in treating Alzheimer's and Parkinson's diseases. The trend in the company's EPS forecast reflects market expectations, where the 33.60 mark indicates the current valuation level. While a team of leading neurologists strives for a scientific breakthrough, the lack of profit and the risk of new share issuances create significant pressure on the stock price.
ANVS (Annovis Bio Inc): פילוחים אנליטיים ודוחות לפי אינדיקטורים

This indicator reflects the consensus earnings per share (EPS) forecast, measuring the expected net yield dynamics of the business for the coming year. An increase in this metric signals market optimism, although an excessive surge may indicate inflated expectations and the risk of a correction. By analyzing the daily price chart of consensus EPS growth estimates for next year, an investor will see the impact of buntianesan's clinical trial successes and FDA approval prospects on the future capitalization of Annovis Bio, Inc. (ANVS).